The efficacy, safety and usefulness of injectable ciprofloxacin (CPFX) were investigated in a clinical study involving treatment of patients with severe and/or refractory infections in the internal medicine field. The test drug was administered by intravenous drip infusion at a dose of 300 mg (as CPFX), twice daily for 3 to 14 days. A total of 66 cases were enrolled in this study: 16 cases with chronic bronchitis, 23 with infectious bronchiectasis, 20 with secondary infection with chronic respiratory disease and 2 with empyema, but 5 cases had ineligible diseases. The clinical efficacy rate was 69.1% (38/55 cases), being 92.3% (12/13) for chronic bronchitis, 59.1% (13/22) for infectious bronchiectasis, 72.2% (13/18) for secondary infection with chronic respiratory disease. The subtotals were 71.7% (38/53) for the above chronic lower RTIs and 0/2 for empyema. The efficacy rate in poor responders to antibiotic pretreatment was 66.7% (8/12 cases). The elimination rate of causative organisms was 65.7% (23/35 strains), in terms of bacteriological efficacy. Side effects were noted in 11.3% (7/62) with 10 events. The major signs and symptoms were central nervous system disorders and gastro-intestinal symptoms, all of which were mild to moderate, and disappeared during treatment or after the completion of treatment or drug discontinuation. Abnormal laboratory findings were seen in 13.1% (8/61) with 19 events, mostly GOT, GPT and/or γ -GTP elevation. In the evaluation of overall safety, a safety rate of 77.4% (48/62 cases) was obtained, yielding a 62.1% (36/58 cases) usefulness rate. Therefore, the present study confirmed good effectiveness and safety for injectable CPFX in the treatment of severe and/or refractory chronic airway infections.
|Number of pages||3|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - 1997|
ASJC Scopus subject areas
- Pharmacology (medical)